CD274 and neoplasm: Using in vitro and in vivo models, the study showed that decitabine induces DNA hypomethylation which enhances tumor PD-L1 expression via an epigenetic mechanism, improving the therapeutic efficacy of anti-PD-L1 immunotherapy.